Imprimis begins shipping from FDA-registered outsourcing facility

Imprimis Pharmaceuticals’ New Jersey outsourcing facility has begun shipping sterile ophthalmic medications to select customers without a patient-specific prescription, according to a company press release. The company’s Dropless Therapy injectable and LessDrops topical formulations will also be available in the next few weeks, the release said.

Full Story →